IN Brief:
- EU institutions have reached a provisional agreement reserving 31 meat-related terms for meat products only.
- The move captures cell-cultured products and would restrict the use of terms including beef, chicken, steak, ribs, and bacon.
- The decision adds another commercial hurdle for cultivated meat companies already navigating novel-food approval and slow market adoption.
Aleph Farms is among the cultivated meat companies facing a more restrictive commercial landscape in Europe after EU institutions reached a provisional agreement reserving a wide set of meat-related terms for meat products only, including where cell-cultured products are concerned.
The agreement forms part of wider changes to the common market organisation framework and covers 31 protected terms. Those include species names such as beef, veal, pork, poultry, chicken, turkey, duck, lamb, and goat, as well as product and cut descriptors including steak, ribs, wing, breast, loin, sirloin, tenderloin, brisket, liver, thigh, ribeye, T-bone, rump, drumstick, and bacon. Under the agreed text, those terms would be reserved for meat products only and could not be used for products that do not contain meat, including cell-cultured foods.
The immediate effect is on labelling and positioning. Cultivated meat producers are still working through novel-food pathways, scale-up, and commercial partnerships, and product language is one of the few tools they have to explain clearly what a product is meant to replace. Restricting familiar descriptors makes that process more difficult, particularly for companies developing whole-cut products rather than nuggets, meatballs, or blended formats.
That issue is especially sharp for Aleph Farms, whose cultivated beef platform has focused on steak-like formats. A name such as steak does more than suggest flavour or provenance; it also signals shape, cut, and expected use. Removing that language does not prevent product development, but it complicates how those products are described to regulators, retailers, and eventual customers. In a category that is already carrying a heavy burden of explanation, additional ambiguity is unlikely to help.
The agreement still requires formal endorsement by both the Council and the European Parliament before final adoption, but the direction is now clear. Europe is moving to fix terminology restrictions before cultivated meat has established any real commercial footprint in the bloc. That says much about the current regulatory mood around novel proteins. Rules are being set early, and in ways that may narrow the commercial playbook before the category has had much chance to prove itself.
The timing is awkward for companies trying to build a multi-market route to scale. Aleph Farms has already secured approval in Israel and has applications under review in other markets, including the United Kingdom, Singapore, and Thailand. Other cultivated meat businesses are taking a similar approach, hoping that a patchwork of approvals across more receptive jurisdictions will generate enough volume, capital confidence, and manufacturing learning to support broader expansion later on.
Europe’s latest move adds another layer of fragmentation to that picture. Novel-food approval is already slow, manufacturing economics remain difficult, and consumer familiarity is still limited. A tighter terminology framework does not stop the category, but it creates another practical barrier at a stage when commercial simplicity is already in short supply. Companies will need to work harder on alternative naming, product education, and retailer communication if they still want to preserve a recognisable proposition on shelf.
There is also a wider implication beyond cultivated meat alone. Europe has spent years arguing over the naming of plant-based dairy and meat alternatives, and the inclusion of cell-cultured products in this framework shows the same regulatory instincts are now extending into the next generation of alternative protein. For processors watching the category, that is a reminder that technical feasibility and regulatory feasibility rarely move at the same speed. In cultivated meat, the science is still chasing cost and scale, while regulation is already shaping how the eventual products may be described, sold, and understood.
The likely result is that cultivated meat companies will continue to prioritise markets where both approval and commercial language are clearer. Europe may still become part of that story, but it is doing little at present to make the route easier.
